Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Sales: 2014-2025

Historic Return on Sales for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to -4.43%.

  • Ocular Therapeutix's Return on Sales fell 217.00% to -4.43% in Q3 2025 from the same period last year, while for Sep 2025 it was -4.43%, marking a year-over-year decrease of 217.00%. This contributed to the annual value of -2.59% for FY2024, which is 106.00% down from last year.
  • Ocular Therapeutix's Return on Sales amounted to -4.43% in Q3 2025, which was down 12.70% from -3.93% recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Return on Sales ranged from a high of -1.52% in Q3 2023 and a low of -4.43% during Q3 2025.
  • Its 3-year average for Return on Sales is -2.41%, with a median of -1.91% in 2024.
  • Per our database at Business Quant, Ocular Therapeutix's Return on Sales skyrocketed by 1,063bps in 2021 and then tumbled by 217bps in 2025.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Return on Sales stood at -1.95% in 2021, then climbed by 30bps to -1.65% in 2022, then rose by 11bps to -1.54% in 2023, then tumbled by 106bps to -2.59% in 2024, then plummeted by 217bps to -4.43% in 2025.
  • Its Return on Sales was -4.43% in Q3 2025, compared to -3.93% in Q2 2025 and -3.29% in Q1 2025.